Led by Dr Daniel Price of Te Whare Wānanga o Waitaha | University of Canterbury (UC’s) School of Earth and Environment, the ...

All three drugs are being positioned as an off-the-shelf alternative to CAR-T therapies ... approved for squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.

Novo Nordisk’s bid to provide a once-weekly basal insulin product for people with diabetes, reducing the number of injections needed, has hit a major hurdle in the US. The FDA sent the Danish ...